Market Place
Sourcing Support
Carisma Therapeutics Announces Strategic Restructuring of Pipeline
09 Dec 2024 //
PR NEWSWIRE
Carisma axes sole clinical candidate, lays off 34% of staff
09 Dec 2024 //
FIERCE BIOTECH
Carisma to Participate in Evercore ISI HealthCONx Conference
27 Nov 2024 //
PR NEWSWIRE
Carisma Presents Data on Macrophages at AASLD Liver Meeting
17 Nov 2024 //
PR NEWSWIRE
Carisma`s Moderna-powered cell therapy shrinks tumors in mice
07 Nov 2024 //
FIERCE BIOTECH
Carisma Reports Q3 2024 Financial Results & Business Highlights
07 Nov 2024 //
PR NEWSWIRE
Carisma Therapeutics Presents New Anti-GPC3 CAR-M Data at SITC 2024
05 Nov 2024 //
PR NEWSWIRE
Carisma Therapeutics Announces Changes to its Board of Directors
30 Oct 2024 //
PR NEWSWIRE
Carisma Therapeutics Announces Upcoming Presentations at SITC 2024
04 Oct 2024 //
PR NEWSWIRE
Carisma And Moderna Expand In Vivo Cell Therapy To Autoimmune Diseases
11 Sep 2024 //
FIERCE BIOTECH
Carisma And Moderna Expand CAR-M Therapy Collaboration
10 Sep 2024 //
PR NEWSWIRE
Carisma Therapeutics to Present at Upcoming Conferences
03 Sep 2024 //
PR NEWSWIRE
Carisma Therapeutics Reports Q2 2024 Results And Business Highlights
08 Aug 2024 //
PR NEWSWIRE
Carisma Therapeutics Announces Expansion of Its Scientific Advisory Board
06 Aug 2024 //
PR NEWSWIRE
Carisma Therapeutics To Present At AASLD Liver Meeting 2024
06 Aug 2024 //
PR NEWSWIRE
Carisma Therapeutics Announces Changes to its Board of Directors
01 Jul 2024 //
PR NEWSWIRE
Carisma Announces Nomination of First In Vivo CAR-M Development Candidate
27 Jun 2024 //
PR NEWSWIRE
Carisma Therapeutics to Participate in the Stifel 2024 Cell Therapy Forum
25 Jun 2024 //
PR NEWSWIRE
Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525
25 Jun 2024 //
PR NEWSWIRE
Carisma Therapeutics Announces Adjournment of Annual Meeting of Stockholders
13 Jun 2024 //
PR NEWSWIRE
Carisma At Jefferies Global Healthcare Conference
30 May 2024 //
PR NEWSWIRE
Carisma Doses First CT-0525 HER2 CAR-Monocyte Patient
16 May 2024 //
PR NEWSWIRE
Carisma Therapeutics Q1 2024 Financials, Business Highlights
09 May 2024 //
PR NEWSWIRE
Carisma Presents Macrophage Anti-Fibrotic Potential Data At ASGCT 2024
08 May 2024 //
PR NEWSWIRE
Turbulence in Pharma: A Wave of Layoffs Sweeps Through the Industry
07 May 2024 //
BIOSPECTRUM ASIA
Carisma Therapeutics to Participate in The Citizens JMP Life Sciences Conference
06 May 2024 //
PR NEWSWIRE
Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer
02 May 2024 //
PR NEWSWIRE
Carisma to Present at ASCO 2024 Annual Meeting
24 Apr 2024 //
PR NEWSWIRE
Carisma New Data At ASGCT Gene And Cell Therapy Meeting
22 Apr 2024 //
PR NEWSWIRE
Carisma Therapeutics Announces Changes to its Board of Directors
01 Apr 2024 //
PR NEWSWIRE
Carisma Provides Business Update and Reports Q4 and FY23 Financial Results
01 Apr 2024 //
PR NEWSWIRE
Carisma to lay off staff, drop clinical CAR-M program in favor of 2nd candidate
01 Apr 2024 //
ENDPTS
Carisma to Participate in TD Cowen`s 44th Annual Health Care Conference
28 Feb 2024 //
PR NEWSWIRE
Carisma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
21 Dec 2023 //
PR NEWSWIRE
CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration
14 Dec 2023 //
PR NEWSWIRE
Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525
28 Nov 2023 //
PR NEWSWIRE
Carisma Therapeutics to Participate in Evercore ISI HealthCONx Conference
22 Nov 2023 //
PR NEWSWIRE
Carisma Therapeutics Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
PR NEWSWIRE
Carisma Presents Pre-Clinical Proof of Concept for in vivo CAR-M
31 Oct 2023 //
PR NEWSWIRE
Carisma to Present First Results From in vivo CAR-M Collaboration with Moderna
25 Oct 2023 //
PR NEWSWIRE
Carisma Therapeutics to Present at Upcoming Investor Conferences
05 Sep 2023 //
PR NEWSWIRE
Carisma Announces Data from Phase 1 Clinical Trial of CT-0508 at CAR-TCR Summit
01 Sep 2023 //
PR NEWSWIRE
Carisma Therapeutics Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
PR NEWSWIRE
Carisma Announces First Patient Dosed in Ph1 Study of CT-0508 in with KEYTRUDA
28 Jun 2023 //
PR NEWSWIRE
Carisma to be Added to Russell 2000®, Russell 3000® & Russell Microcap® Indexes
26 Jun 2023 //
PR NEWSWIRE
Carisma Therapeutics to Present at Upcoming Investor Conferences in June 2023
05 Jun 2023 //
PR NEWSWIRE
Carisma to Present at Upcoming Healthcare Industry Conferences in June 2023
30 May 2023 //
PR NEWSWIRE
Carisma Therapeutics Reports 1Q 2023FYR &Provides Business Highlights
11 May 2023 //
PR NEWSWIRE
Carisma to Present at Upcoming Healthcare Industry Conferences in May 2023
05 May 2023 //
PR NEWSWIRE
Carisma to Present at American Association for Cancer Research Annual Meeting
14 Apr 2023 //
PR NEWSWIRE
Carisma to Present at Healthcare Industry and Investor Conferences in April 2023
06 Apr 2023 //
PR NEWSWIRE
Carisma Reports Fiscal 2022 Financial Results and Recent Business Highlights
04 Apr 2023 //
PR NEWSWIRE
After sealing reverse merger, Carisma aims for cancer wins
21 Mar 2023 //
FIERCE BIOTECH
Sesen Bio Stockholders Approve Merger with Carisma Therapeutics
02 Mar 2023 //
BUSINESSWIRE
BML Announces Support for Pending Merger with Carisma Therapeutics
15 Feb 2023 //
BUSINESSWIRE
Sesen & Carisma Announce Increased Special Cash Dividend for Pending Merger
14 Feb 2023 //
BUSINESSWIRE
Harvard professor takes on the mantle of Gavi CEO
14 Feb 2023 //
ENDPTS
Carisma Appoints Lin Guey to Scientific Advisory Board
07 Feb 2023 //
PR NEWSWIRE
Carisma Therapeutics Appoints Padmanee Sharma, MD to Scientific Advisory Board
31 Jan 2023 //
PR NEWSWIRE
Sesen Reiterates Confidence that Merger with Carisma is in Interests of Stockholders
26 Jan 2023 //
BUSINESSWIRE
